MULTIMALVAX

A Multi-Stage Malaria Vaccine

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD    more  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Pialek Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.multimalvax.eu/home
Totale costo	8˙063˙004 €
EC contributo	6˙000˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-10-01   -   2016-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Pialek Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801	UK (OXFORD)	coordinator	3˙500˙000.00
2	REITHERA SRL  Organization address address: VIA GAETANO SALVATORE 486 city: Napoli postcode: 80145 contact info Titolo: Prof. Nome: Alfredo Cognome: Nicosia Email: send email Telefono: 390697000000	IT (Napoli)	participant	1˙300˙000.00
3	EUROPEAN VACCINE INITIATIVE - EEIG  Organization address address: IM NEUERHEIMER FELD 307 city: Heidelberg postcode: 69120 contact info Titolo: Dr. Nome: Odile Cognome: Leroy Email: send email Telefono: +49 6221565890 Fax: +49 6221565727	DE (Heidelberg)	participant	700˙000.00
4	UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6  Organization address address: Place Jussieu 4 city: PARIS postcode: 75252 contact info Titolo: Mr. Nome: Thomas Cognome: Wiest Email: send email Telefono: +33 1 44 27 97 58	FR (PARIS)	participant	300˙000.00
5	GLAXOSMITHKLINE VACCINES SRL  Organization address address: Via Fiorentina 1 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Francesco Cognome: Gulli Email: send email Telefono: 390577000000	IT (SIENA)	participant	200˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas. Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life-cycle allow testing of a multi-stage multi-component vaccine for the first time, with strong chances of success. These advances are i) the availability of a new vectored prime-boost vaccination regime based on the Okairos chimpanzee adenovirus technology that has been found to induce exceptionally potent CD8 T cell responses and high titre antibodies against multiple malaria antigens; ii) the development of an improved version of the leading partially protective RTS,S sporozoite vaccine candidate, termed R21, that lacks the excess of HBsAg in RTS,S; iii) the identification, using a vector technology screen, of the blood-stage antigen RH5 as the first antigen to induce potent strain-transcending neutralisation of blood-stage parasites in in vitro growth inhibition assays; and iv) the demonstration that vector-induced antibodies against two mosquito-stage antigens can induce 100% transmission blocking against field isolates of P. falciparum in Africa. We will undertake four phase I / II clinical trials to assess the pre-erythrocytic, blood-stage and mosquito-stage components individually, and then together, using state-of-the art immunomonitoring, key functional assays of vaccine-induced immunogenicity, and sporozoite and blood-stage parasite challenges to measure efficacy prior to field testing. This SME-led collaboration of a leading SME, two universities, the major European product development partnership for malaria vaccines, and a global pharmaceutical company will provide complementary abilities to accelerate development of this promising product.'

Introduzione (Teaser)

Malaria continues to affect millions of people worldwide. Vaccine development has been one of the main struggles of health research globally.